5 Key Takeaways

• 1

  The FDA has expanded Tzield approval to children as young as one year with stage 2 type 1 diabetes, allowing earlier intervention.

• 2

  The FDA plans to phase out animal testing for monoclonal antibodies, promoting human-relevant testing methods like AI and organ-on-a-chip.

• 3

  AstraZeneca's tozorakimab significantly reduced COPD exacerbations in a Phase III trial, showing broad potential applicability across patient populations.

• 4

  Dupixent has been approved in the EU for children aged 2 to 11 with chronic hives, marking the first targeted therapy for this age group.

• 5

  Moderna's mCOMBRIAX, a combination flu-COVID vaccine, received EU approval, demonstrating non-inferiority and higher immunogenicity in Phase III trials.